300194.SZ
Fuan Pharmaceutical (Group) Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 3.91
−0.51%Aug 26, 2026, 08:27 UTC
Fuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7748 million yuan, down 15.33% year-on-year.
Source:Aug 3, 2026, 07:50 UTC
Fu'an Pharmaceutical and its wholly-owned subsidiaries Tianheng Pharmaceutical, Zhichu Pharmaceutical, and Renmin Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with three drugs (Nicardipine Hydrochloride Injection, Teicoplanin for Injection, and Isavuconazole Sulfate for Injection) provisionally selected, with the procurement period running from the effective date of the selection results to December 31, 2029.
Source:Jul 24, 2026, 08:06 UTC
Fuan Pharmaceutical's wholly-owned subsidiary Tianheng Pharmaceutical received a drug registration certificate from the National Medical Products Administration for Bromhexine Hydrochloride Injection, specification 2ml:4mg.
Source:Jul 2, 2026, 07:44 UTC
Fuan Pharmaceutical's deputy general manager Feng Jing resigned due to job adjustment, effective upon delivery of resignation report.
Source: